OR4D6 Antibody

What is OR4D6 and what applications are appropriate for OR4D6 antibody?

OR4D6 (Olfactory receptor 4D6, also known as Olfactory receptor OR11-250) is a G-protein-coupled receptor involved in olfactory signal transduction. This receptor belongs to the large family of olfactory receptors that interact with odorant molecules to initiate neuronal responses that trigger smell perception .

The rabbit polyclonal antibody against OR4D6 has been validated for:

• Western blot (WB) applications at dilutions of 1:500-1:1000

• ELISA at higher dilutions of approximately 1:20000

While immunohistochemistry applications aren't explicitly validated for OR4D6 antibody in the provided data, similar olfactory receptor antibodies have been successfully used in immunohistochemical studies of olfactory tissues.

What are the key specifications of commercially available OR4D6 antibodies?

Available OR4D6 antibodies have the following specifications:

This rabbit polyclonal antibody is purified from serum using antigen affinity chromatography with the immunizing peptide, ensuring higher specificity compared to crude serum antibodies .

How should OR4D6 antibody be stored and handled to maintain optimal activity?

To preserve antibody functionality, OR4D6 antibody requires:

• Shipping at 4°C to maintain protein stability during transportation

• Long-term storage at -20°C in aliquots to minimize repeated freeze/thaw cycles

• Avoidance of multiple freeze/thaw cycles which can cause protein denaturation and loss of binding activity

• Storage in the provided buffer formulation (PBS with 50% glycerol and 0.02% sodium azide, pH 7.4), which helps stabilize antibody structure

• Handling using proper PPE due to the presence of sodium azide (0.02%), which is toxic

For optimal results, it's recommended to prepare smaller working aliquots upon receipt and store them at -20°C to avoid repeated freeze/thaw cycles that can compromise antibody performance.

What controls should be included when using OR4D6 antibody?

When conducting experiments with OR4D6 antibody, include the following controls:

• Positive control: Cell lines known to express OR4D6 (such as LOVO cells based on the western blot validation data)

• Negative control: Cells not expected to express the target (NIH/3T3 cells can serve as negative controls as seen in western blot data)

• Blocking peptide control: Running parallel samples with antibody pre-incubated with the immunizing peptide to verify binding specificity

• Isotype control: Use of non-specific rabbit IgG (such as products A82272 or A17360) at matched concentrations to identify any non-specific binding

• No primary antibody control: Omitting the primary antibody to assess secondary antibody background

These controls are essential for validating experimental results and ensuring the observed signals are specific to the OR4D6 protein.

How can computational modeling assist in optimizing OR4D6 antibody specificity?

Computational modeling approaches can significantly enhance OR4D6 antibody specificity through:

• Biophysics-informed models that identify distinct binding modes associated with specific ligands, allowing prediction of antibody-target interactions beyond experimental observations

• Neural network parameterization of binding energies that can distinguish between desired and undesired interactions

• Sequence-function relationship analysis that helps identify critical residues influencing specificity

• Energy minimization algorithms that can predict optimal amino acid sequences for either specific binding to OR4D6 or cross-specificity across multiple targets

• Integration of phage display experimental data with computational predictions to validate and refine specificity profiles

These computational approaches are particularly valuable when designing antibodies that need to discriminate between highly similar epitopes, such as distinguishing OR4D6 from other closely related olfactory receptors in the OR4 family.

What methodologies can be employed to address potential false-negative results when using OR4D6 antibody?

False-negative results represent a significant challenge in antibody-based detection systems. For OR4D6 antibody applications, researchers should consider:

• Evaluating multiple antibody concentrations beyond the recommended range to account for varying expression levels

• Testing different epitope retrieval methods, particularly for fixed tissues where epitope masking may occur

• Employing multiple detection systems, as sensitivity varies significantly between platforms (sensitivity differences of up to 17.5% have been observed between different antibody detection systems)

• Incorporating positive controls with known OR4D6 expression levels in every experimental run

• Using more sensitive detection methods like chemiluminescence or tyramide signal amplification for low-abundance targets

• Testing alternative OR4D6 antibodies targeting different epitopes when available

Research indicates that some antibody-platform combinations can yield false-negative rates of up to 20.6%, highlighting the importance of careful methodology selection and validation.

How can phage display technology be applied to generate OR4D6 antibodies with custom specificity profiles?

Phage display represents a powerful approach for generating OR4D6 antibodies with tailored specificity profiles:

• Library creation: Establish a diverse antibody library with variations in complementarity-determining regions (CDRs), particularly CDR3, which is critical for binding specificity

• Selection strategy: Design selection protocols using purified OR4D6 protein with appropriate counter-selection against closely related olfactory receptors

• Multiple rounds of selection: Perform 2-3 rounds of selection with increasing stringency to enrich for specific binders

• High-throughput sequencing: Analyze selected antibody populations to identify enriched sequences

• Computational analysis: Apply biophysics-informed models to distinguish different binding modes

• Custom specificity design: Optimize energetic functions to generate either highly specific OR4D6 binders or cross-specific antibodies that recognize multiple defined targets

This integrated experimental-computational approach allows researchers to go beyond the limitations of traditional selection methods, enabling the design of antibodies with precisely defined specificity profiles against OR4D6.

What are the critical factors for validating OR4D6 antibody specificity in experimental settings?

Rigorous validation of OR4D6 antibody specificity requires:

• Western blot validation using:

  • Positive and negative control cell lines

  • Competing peptide blocking experiments

  • Detection of the expected 35kDa band with appropriate controls

• Genetic validation approaches:

  • Testing in OR4D6 knockout/knockdown systems

  • Overexpression systems with tagged OR4D6 constructs

  • Correlation of antibody signal with mRNA expression levels

• Cross-reactivity assessment:

  • Testing against other olfactory receptors, particularly those with high sequence homology

  • Peptide array analysis to map exact binding epitopes

  • Identification of potential off-target binding partners

• Application-specific validation:

  • Immunoprecipitation followed by mass spectrometry

  • Immunohistochemistry correlation with in situ hybridization

  • Testing in multiple relevant tissue types

Complete validation requires employing multiple orthogonal techniques to confirm antibody specificity before using it in critical research applications.

What is the optimal protocol for using OR4D6 antibody in Western blot applications?

For optimal Western blot detection of OR4D6:

• Sample preparation:

  • Prepare cell/tissue lysates using RIPA buffer supplemented with protease inhibitors

  • Use LOVO cells as positive control, NIH/3T3 cells as negative control

  • Determine protein concentration by BCA or Bradford assay

• Electrophoresis and transfer:

  • Load 20-40μg protein per lane on 10-12% SDS-PAGE gels

  • Transfer to PVDF membrane at 100V for 60-90 minutes in cold transfer buffer

• Immunoblotting:

  • Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with OR4D6 antibody at 1:500-1:1000 dilution in 5% BSA/TBST overnight at 4°C

  • Wash 3x with TBST, 5 minutes each

  • Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 3x with TBST, 5 minutes each

  • Develop using enhanced chemiluminescence (ECL) detection

• Expected results:

  • OR4D6 band should appear at approximately 35kDa

  • Signal should be present in positive control and absent in negative control

  • Signal should be blocked when antibody is pre-incubated with immunizing peptide

This protocol can be optimized for specific sample types by adjusting antibody concentration, incubation times, and detection methods.

What methodological approaches can enhance the sensitivity of OR4D6 detection in low-expression samples?

When working with samples having low OR4D6 expression levels:

• Sample enrichment:

  • Immunoprecipitate OR4D6 protein before Western blot

  • Use larger amounts of starting material

  • Enrich for membrane fractions where GPCRs like OR4D6 localize

• Signal amplification:

  • Employ more sensitive ECL substrates (femto-level detection systems)

  • Use tyramide signal amplification for immunohistochemistry

  • Consider biotin-streptavidin amplification systems

• Detection optimization:

  • Increase antibody concentration to 1:250-1:500 (while monitoring background)

  • Extend primary antibody incubation time to 48 hours at 4°C

  • Use high-sensitivity imaging systems with longer exposure times

• Protocol modifications:

  • Reduce washing stringency slightly (shorter wash times)

  • Optimize blocking conditions to reduce background while preserving signal

  • Consider alternative buffers that might better preserve epitope accessibility

Sensitivity testing shows that optimized protocols can achieve detection limits in the low nanogram range for membrane proteins like olfactory receptors.

How can OR4D6 antibody be effectively utilized in ELISA applications?

For ELISA applications using OR4D6 antibody:

• Direct ELISA setup:

  • Coat plates with target protein/peptide at 1-10μg/ml in carbonate buffer (pH 9.6)

  • Block with 5% BSA in PBS for 2 hours at room temperature

  • Apply OR4D6 antibody at 1:20000 dilution (much more dilute than for Western blot)

  • Detect with HRP-conjugated anti-rabbit secondary antibody

  • Develop with TMB substrate and read at 450nm

• Sandwich ELISA considerations:

  • Requires a capture antibody against a different OR4D6 epitope

  • OR4D6 polyclonal can serve as detection antibody at 1:20000 dilution

  • Consider biotinylated detection antibody with streptavidin-HRP for enhanced sensitivity

• Competitive ELISA approach:

  • Pre-incubate OR4D6 antibody with sample containing unknown amount of OR4D6

  • Add mixture to plates coated with known OR4D6 protein/peptide

  • Reduced signal indicates presence of OR4D6 in the sample

ELISA applications require significantly higher dilutions (1:20000) compared to Western blot (1:500-1:1000) due to the higher sensitivity of the ELISA format.

What methods can be used to quantitatively assess OR4D6 antibody sensitivity and specificity?

To quantitatively evaluate OR4D6 antibody performance:

• Sensitivity assessment:

  • Create standard curves using recombinant OR4D6 protein at known concentrations

  • Calculate limit of detection (LOD) and limit of quantification (LOQ)

  • Determine sensitivity as the percentage of true positives correctly identified

  • Compare signal-to-noise ratios across different detection systems

• Specificity calculations:

  • Test against closely related olfactory receptors to calculate cross-reactivity percentages

  • Perform competitive binding assays with related and unrelated proteins

  • Calculate specificity as the percentage of true negatives correctly identified

• ROC curve analysis:

  • Plot sensitivity vs. 1-specificity across different antibody concentrations

  • Calculate area under the curve (AUC) as a comprehensive performance metric

  • Determine optimal cutoff values for specific applications

• Confidence interval calculation:

  • For example, a properly validated antibody might achieve 95.83% sensitivity (95% CI 88.30-99.13%) when used in optimal conditions

These quantitative assessments are essential for comparing antibody performance across different research settings and applications.

What are common causes of false-negative results when using OR4D6 antibody and how can they be addressed?

False-negative results with OR4D6 antibody can stem from several factors:

• Epitope masking:

  • Problem: Fixation or sample preparation may obscure the antibody binding site

  • Solution: Test alternative fixation methods or antigen retrieval techniques

• Low expression levels:

  • Problem: OR4D6 expression below detection threshold

  • Solution: Use signal amplification methods or more sensitive detection systems

• Platform incompatibility:

  • Problem: Some antibody-platform combinations show up to 17.5% lower sensitivity

  • Solution: Test the antibody across multiple detection platforms to identify optimal systems

• Protein degradation:

  • Problem: Target protein degraded during sample preparation

  • Solution: Use fresh samples, add protease inhibitors, optimize extraction conditions

• Buffer incompatibility:

  • Problem: Buffer components interfering with antibody binding

  • Solution: Test alternative buffer systems, especially for membrane proteins like OR4D6

Research demonstrates that antibody sensitivity can vary significantly between platforms, with false-negative rates ranging from 0% to 20.6% depending on the detection system used.

How can researchers address batch-to-batch variability in OR4D6 antibody performance?

To manage batch-to-batch variability:

• Reference standard approach:

  • Maintain a reference standard from a well-characterized batch

  • Compare new batches against this standard using consistent protocols

  • Document relative performance metrics for normalization

• Parallel testing strategy:

  • Test new batches alongside current batch before depletion

  • Create overlapping usage periods rather than abrupt transitions

  • Develop batch correction factors for quantitative applications

• Expanded validation:

  • Perform comprehensive validation with each new batch

  • Verify specificity using blocking peptides and control samples

  • Document batch-specific optimal working dilutions

• Internal controls:

  • Include consistent positive and negative controls with every experiment

  • Use control cell lines with known OR4D6 expression levels

  • Consider creating stable reference standards (e.g., fixed cell preparations)

Implementing these approaches can minimize the impact of batch variability on experimental outcomes and improve research reproducibility.

What quality control measures should be implemented when working with OR4D6 antibody in long-term research projects?

For long-term research involving OR4D6 antibody:

• Performance monitoring:

  • Establish baseline performance metrics at project initiation

  • Regularly test antibody using standard samples to track potential degradation

  • Document signal intensity, background levels, and signal-to-noise ratios over time

• Storage optimization:

  • Create multiple small aliquots to minimize freeze-thaw cycles

  • Monitor storage temperature consistency with temperature logs

  • Establish maximum storage duration based on validated stability data

• Validation maintenance:

  • Re-validate antibody performance at defined intervals

  • Test against positive and negative controls regularly

  • Perform periodic blocking peptide controls to confirm specificity

• Documentation systems:

  • Maintain detailed records of antibody lot numbers, receipt dates, and aliquoting

  • Document all experimental conditions when antibody performance is evaluated

  • Create standardized protocols for all applications to minimize variation

• Cross-validation:

  • Periodically confirm key findings using orthogonal methods

  • Consider using multiple antibodies targeting different OR4D6 epitopes for critical results

  • Correlate protein detection with mRNA expression data when possible

These comprehensive quality control measures ensure consistent antibody performance throughout extended research projects.

How can researchers optimize blocking conditions to reduce non-specific binding when using OR4D6 antibody?

To minimize non-specific binding:

• Blocking agent selection:

  • Test different blocking proteins (BSA, non-fat milk, normal serum, commercial blockers)

  • For OR4D6 (a membrane protein), BSA often performs better than milk proteins

  • When using milk, ensure it's not causing cross-reactivity with the secondary antibody

• Blocking optimization:

  • Test different concentrations (3-5% is typical, but up to 10% may be needed)

  • Optimize blocking duration (1-2 hours at room temperature or overnight at 4°C)

  • Consider adding 0.1-0.3% Triton X-100 or Tween-20 to reduce hydrophobic interactions

• Antibody diluent considerations:

  • Prepare antibody in the same blocking solution for consistency

  • Add 0.05-0.1% Tween-20 to reduce background

  • For problematic samples, include 1-5% of the host species serum of the secondary antibody

• Pre-absorption techniques:

  • For high background, pre-absorb primary antibody with the negative control sample

  • Prepare a membrane with negative control proteins and incubate antibody before use

  • For tissue samples, consider liver powder pre-absorption to reduce non-specific binding

Systematic optimization of these parameters can significantly improve signal-to-noise ratios in OR4D6 detection experiments.

What emerging technologies might enhance future research applications of OR4D6 antibody?

Emerging technologies with potential to revolutionize OR4D6 antibody applications include:

• Advanced antibody engineering:

  • Computational design of synthetic antibodies with enhanced specificity

  • Single-domain antibodies that can access epitopes unreachable by conventional antibodies

  • Bispecific antibodies that can simultaneously target OR4D6 and reporter molecules

• Novel detection platforms:

  • Single-molecule detection systems for ultra-sensitive OR4D6 quantification

  • Super-resolution microscopy for subcellular localization studies

  • Microfluidic antibody arrays for high-throughput screening

• Integrated computational approaches:

  • Machine learning models that predict antibody-antigen interactions

  • Molecular dynamics simulations of binding energetics

  • Structure-based epitope mapping for rational antibody design

• Validation technologies:

  • CRISPR-engineered cell lines with epitope-tagged endogenous OR4D6

  • Proximity labeling methods for identifying interaction partners

  • Highly multiplexed detection systems for simultaneous analysis of multiple olfactory receptors

These technologies promise to expand the capabilities of OR4D6 antibody-based research and overcome current limitations in specificity and sensitivity.